Pemetrexed Treatment Guidelines for Cancer

Primary Indications and Regimens

The National Comprehensive Cancer Network recommends first-line therapy for unresectable malignant pleural mesothelioma (MPM) with pemetrexed 500 mg/m² plus cisplatin 75 mg/m² every 3 weeks (category 1 recommendation) 3, 4
For patients who cannot tolerate cisplatin, the National Comprehensive Cancer Network suggests an alternative regimen of pemetrexed 500 mg/m² plus carboplatin AUC 5 every 3 weeks 4, 5
The National Comprehensive Cancer Network also recommends a triplet therapy option of pemetrexed 500 mg/m² plus cisplatin 75 mg/m² plus bevacizumab 15 mg/kg every 3 weeks for patients ≤75 years with good performance status and no significant cardiovascular history 4, 6

The American College of Chest Physicians and other medical societies emphasize the importance of vitamin supplementation, including folic acid and vitamin B12, when administering pemetrexed, with vitamin B12 1000 μg intramuscularly starting at least 1 week before first pemetrexed dose and continuing every 9 weeks 1, 2

The American Society of Clinical Oncology recommends a treatment duration of 4-6 cycles for front-line therapy, after which patients with stable or responding disease should take a break from chemotherapy rather than continuing maintenance therapy 7
Maintenance pemetrexed is not recommended due to insufficient evidence of benefit, as stated by the American Society of Clinical Oncology and other medical organizations 7, 6
Retreatment with pemetrexed-based chemotherapy may be considered for patients who achieved durable (>6 months) disease control with first-line pemetrexed-based chemotherapy, according to the American Society of Clinical Oncology 7, 8

The National Comprehensive Cancer Network advises that patients with sarcomatoid histology should not undergo surgical cytoreduction but may still receive pemetrexed-based chemotherapy 8
For select asymptomatic patients with epithelial mesothelioma and low disease burden, observation may be considered before initiating systemic therapy, as suggested by the American Society of Clinical Oncology 7

The National Comprehensive Cancer Network notes that common adverse events associated with pemetrexed include hematologic toxicities such as neutropenia, leukopenia, and anemia, as well as non-hematologic toxicities like fatigue, nausea, vomiting, and dyspnea 3, 4

The American College of Chest Physicians states that pemetrexed is contraindicated in patients with severe renal impairment, and the routine substitution of carboplatin for cisplatin is not recommended unless patients have contraindications to cisplatin 2
Clinical trials should be considered for patients with disease progression after first-line therapy due to limited second-line options, as recommended by the American Society of Clinical Oncology 7
Bevacizumab should not be added to pemetrexed/cisplatin in patients with PS 2, substantial cardiovascular comorbidity, uncontrolled hypertension, age >75, or bleeding/clotting risk, according to the American Society of Clinical Oncology 8